Drug interactions
Efgartigimod / hyaluronidase sc + Ramucirumab
Severity: Moderate
Efgartigimod / hyaluronidase sc and Ramucirumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Subcutaneous efgartigimod blocks the neonatal Fc receptor, which may speed clearance of IgG1 antibodies such as ramucirumab and lower exposure.
What this interaction means in plain words
Efgartigimod / hyaluronidase sc and Ramucirumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
FcRn blockade reduces IgG recycling and shortens the half-life of IgG monoclonal antibodies.
What to do
Monitor for reduced ramucirumab efficacy; consider alternatives if long-term combination is necessary.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod / hyaluronidase sc and Ramucirumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ramucirumab
- Efgartigimod alfa + Ramucirumab Moderate
Frequently asked questions
Can I take Efgartigimod / hyaluronidase sc with Ramucirumab?
MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Ramucirumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor, which may speed clearance of IgG1 antibodies such as ramucirumab and lower exposure.
How serious is the interaction between Efgartigimod / hyaluronidase sc and Ramucirumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced ramucirumab efficacy; consider alternatives if long-term combination is necessary.
What other medicines interact with Ramucirumab?
MediHelp also lists interactions of Ramucirumab with, for example, Efgartigimod alfa. The full list is on the Ramucirumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
